CG Oncology Up 14% as Nasdaq Fell 2.5%: A Phase 3 Filing
On Nov. 16, CG Oncology rose 13.95%, Telus 12.19% and Molina 11.27%. Only one move had a company filing behind it.
15 article(s) on Korean Biotech stocks, checked against filings and numbers.
On Nov. 16, CG Oncology rose 13.95%, Telus 12.19% and Molina 11.27%. Only one move had a company filing behind it.
On Nov. 12, Mobility Global rose 16.11% (earnings 8-K), Chagee 9.57% (special dividend, reported) and Belite Bio 8.99% (results and FDA timing, reported).
On Nov 11, as KOSDAQ rose 5.62%, MedPacto, Noul and Ecocap closed limit-up. MedPacto has no filing, Noul has a largest-shareholder change filing, and Ecocap has a buyback trust filing.
On Nov. 10 U.S. indexes fell while AAON gained 19.31%, Csquare 14.73% and Acadia 10.79%; the reasons were confirmed by filings for two and by news reports alone for one.
Seegene fell 20.81% after its Q3 earnings disclosure. Alteogen fell 16.81% on reports of U.S. drug price pressure, with no company filing.
On a day when U.S. indexes fell 4% to 5%, AppLovin rose 31%, Encore 26% and ADMA 26%. All three have earnings 8-Ks; how solid each rally is differs.
Kyndryl and Duolingo rose on earnings; Rhythm Pharmaceuticals rose on a reported $10 billion AstraZeneca bid that no filing confirms.
On Oct. 23, 2026, Robert Half rose on an earnings 8-K, Genmab on a reported Phase 3 result and Netskope with its sector. Only Robert Half's move has a filing behind it.
On Oct. 22, Biohaven Ltd. (+25%) had an FDA review-acceptance 8-K and Pool Corporation (+14%) had an earnings 8-K, while no reason was found for Concentrix Corporation (+14%).
On Oct. 20, Braze (BRZE) rose 51.7% on a filed Salesforce deal, while Lionsgate Studios (LION) and SELLAS Life Sciences (SLS) rose about 14% without filings.
On Oct. 19, Disc Medicine (+38.9%), Cleveland-Cliffs (+16.3%) and Veradermics (+12.4%) rose on filing-backed news. Disc Medicine drew a reported $350M offering after the close.
HD Hyundai Electric fell with the market; no clear reason is confirmed for Summit Therapeutics.
Liquidia rose 26.6% after an 8-K showed a settlement of patent and trade-secret litigation with United Therapeutics.
Sandslab, RaonSecure and HLB Pharmaceutical hit the 30% daily limit on Oct 6, with reasons found only in news reports.
United Therapeutics (patent ruling, +12.55%), Rogers (investor-day targets, +10.73%) and FormFactor (buy rating, +9.59%) rose on Sept. 30 for different reasons of different strength.